Rasilamlo regulatory update

Germany's Federal Joint Committee (G-BA) issued a final assessment that found "no additional benefit" for Rasilamlo aliskiren/amlodipine from Novartis for patients with hypertension for whom therapy with aliskiren or amlodipine alone is not sufficient. The assessment is in line with a February preliminary assessment from the Institute for Quality and Efficiency in Health Care (IQWiG). Rasilamlo will be added to the reference pricing system; Novartis will not be able to negotiate (see BioCentury, Feb. 20). ...